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Introduction 
Thyroid disorders are common in women of reproductive age (1). Overt thyroid 
disease carries an increased risk of adverse pregnancy outcomes including 
miscarriages, stillbirths, and neuro-intellectual impairment in the offspring (2, 3). 
These adverse events also occur to some extent in patients with subclinical 
hypothyroidism (2). Crucially, the deleterious effects of overt disease are preventable 
by prompt correction of thyroid dysfunction (4-6). Thyroid hormones are essential for 
normal fetal growth and brain development and in early gestation the fetus wholly 
relies on maternal thyroxine delivery up until the onset of fetal thyroid hormone 
secretion at 14-18 weeks (7). This early phase of fetal life coincides with important 
developmental events such as neuronal migration, proliferation, and neural tube 
formation, and thus represents a period of critical vulnerability during which maternal 
thyroid dysfunction could have lasting repercussions (7). Effective preconception 
management is a key strategy for optimising thyroid disease outcomes in pregnancy 
but focused reviews on preconception care are scarce. In this review we highlight the 
rationale and evidence for current preconception strategies in the management of 
thyroid dysfunction.  
Physiological adaptations of thyroid function in pregnancy 
Normal pregnancy is characterised by a series of dynamic and highly orchestrated 
alterations in thyroid hormone economy (figure 1) (8). These changes are set in 
motion from the early post-conception period and adapt through gestation to 
increase fetal thyroid hormone delivery in the face of increased iodine requirements 
and peripheral hormone metabolism.  
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Increase in thyroid hormone production 
Serum thyroxine binding globulin (TBG) concentrations start to rise from 6 weeks 
gestation primarily due to oestrogen induced increase in hepatic TBG synthesis (8). 
TBG is the major thyroid hormone transport protein in pregnancy and consequently 
T4 and T3 concentrations increase in parallel, reaching peak levels by mid gestation. 
Levels of free thyroid hormones may fall to a small degree but are generally 
maintained within the normal range in healthy women with adequate iodine nutrition 
and thyroid function (9). Increased thyroid hormone production also results from the 
thyroid stimulatory actions of placental derived human chorionic gonadotropin (hCG). 
hCG has an identical α-subunit to TSH, and so acts on TSH receptors on thyroid 
follicular cells to increase thyroidal T3 and T4 output. The increase in thyroid 
hormone production is in turn accompanied by a fall in serum TSH via pituitary 
thyroid feedback and trough TSH concentrations are reached by 10-12 weeks. 
Lastly, increased thyroid hormone requirements are amplified by thyroid hormone 
peripheral metabolism by the type III inner-ring deiodinase, abundantly expressed in 
placental tissue (8).  
Increase in Iodine requirements 
Iodine requirements increase in pregnancy primarily due to increased renal 
clearance with additional feto-placental losses in later gestation. The thyroid gland 
compensates for these losses by increasing thyroidal iodide uptake and clearance. 
Pregnant women with sufficient iodine nutrition are able to seamlessly implement 
these adaptive mechanisms but in iodine deficient states these changes may fail to 
deliver adequate thyroid hormones to the fetus. Population iodine nutrition remains 
highly variable and even in countries with iodine sufficient status some pregnant 
women do not achieve the minimum recommended daily iodine intake of 250 mcg 
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daily (10). European and American endocrine society guidelines recommend 
antenatal supplementation of 150 mcg of iodine daily but specific recommendations 
in the UK are lacking (10-12).  
Laboratory implications  
The above physiological changes result in a downward shift of gestational TSH 
reference intervals. This change is most marked in the first trimester and varies with 
race and ethnicity. Current guidelines recommend the use of trimester specific 
normative values derived from a representative healthy pregnant population but such 
data is not widely available. A pragmatic TSH upper limit of 2.5 mU/L was previously 
advocated but recent data now shows this to be too low (13). One approach 
suggested in the current guidelines of the American Thyroid Association (ATA) is to 
set the pregnancy reference range at 0.5 mU/L and 0.4 mU/L below the upper and 
lower non-pregnant reference range respectively, reflecting the anticipated 
magnitude of the TSH drop (11). With respect to FT4, the commonly used 
immunoassays are prone to method dependent bias in pregnancy due to changes in 
TBG and albumin concentrations (11, 14). Total T4 is a more predictable alternative 
as it typically rises by 50% of baseline values attaining peak levels by 16 weeks 
gestation (11). More robust methods such as equilibrium dialysis, liquid 
chromatography-tandem mass spectrometry (LC-MS/MS), or FT4 index calculations 
are cumbersome to perform and not routinely used (11).  
Overt hypothyroidism 
Overt hypothyroidism (i.e. low FT4 and elevated TSH) affects 0.3 – 0.5% of the 
population and is ten times more prevalent in females than in males (15). In iodine-
replete countries hypothyroidism is predominantly due to Hashimoto’s thyroiditis 
characterised by the presence of circulating thyroid-specific antibodies namely 
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thyroid peroxidase (TPOAb) and thyroglobulin (TgAb) antibodies. Other common 
causes include thyroidectomy and radioiodine therapy for benign and malignant 
thyroid disease, and globally, iodine deficiency remains relevant in areas with severe 
deficiency. Uncorrected overt hypothyroidism increases the risk of adverse 
pregnancy outcomes such as miscarriages, eclampsia, anaemia, and pre-term births 
(16, 17). The effect of maternal hypothyroidism also affects neuro-intellectual and 
behavioural development in the child (2, 16, 17).  
There is consensus that overt gestational hypothyroidism should be corrected 
although prospective controlled trials are lacking and would be unethical in the light 
of current understanding. However, we can surmise from available observational 
data that it is beneficial to correct gestational hypothyroidism. Several small 
prospective open labelled studies have shown that correction of overt 
hypothyroidism to TSH levels within the reference range yields significant gains in 
reducing fetal loss (4, 18). An analysis of a large community database of 
levothyroxine-treated women showed an incremental increase in miscarriage risk in 
association with rising TSH strata, with the highest risk seen at early gestation TSH 
concentrations exceeding 10 mU/L (OR 3.95, 95% CI 1.87, 8.37) (6).  
Preconception management of hypothyroidism 
The goal of preconception management is to correct hypothyroidism, provide pre-
pregnancy counselling, and pre-emptively increase levothyroxine dose on 
conception. In the absence of a functioning thyroid gland most women with 
hypothyroidism will require an increase in levothyroxine dose to meet gestational 
demands. Studies report a 30-50% increase in requirements although the magnitude 
of this increase and the proportion of patients requiring dose increases is more 
variable (19-21). In practice 25-50% of women have TSH values outside the 
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references ranges in early pregnancy (6, 22, 23) in part due to the post-conception 
TSH rise (23-25) but also a reflection of inadequate thyroid hormone replacement in 
the general population (26, 27). Women with a new diagnosis of hypothyroidism 
should be commenced on full replacement doses of levothyroxine (0.8-1.6 
mcg/kg/day) and advice should be provided on the importance of treatment 
adherence and the need to optimise thyroid hormone replacement before 
conception. Patients should be reassured that levothyroxine is safe in pregnancy and 
that satisfactory pregnancy outcomes are achieved with adequate replacement. 
Liothyronine or desiccated thyroid preparations are not recommended in pregnancy 
as T3 is wholly degraded in the placenta.  
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The preconception TSH target should be similar to the first trimester target of <2.5 
mU/L for levothyroxine treated women (11). Other limits may be more appropriate 
where gestation-specific reference ranges are available (11). Women on 
levothyroxine should be instructed to obtain a thyroid function test and to increase 
their levothyroxine dose once pregnancy is confirmed. Several empirical approaches 
to this has been suggested including doubling the levothyroxine dose for two days a 
week, equating to a 30% increase (20) or increasing the dose by 25 mcg daily in 
patients receiving 100 mcg daily or less and by 50 mcg in those receiving more than 
100 mcg (2). In our practice we favour the latter approach which approximates to 
increases of 25-50%. Two small studies have demonstrated that aiming for a low-
normal preconception TSH (<1.2 mU/L) guarantees a post conception TSH<2.5 
mU/L (24, 25) but the safety of this approach in non-specialist settings requires 
confirmation. Additional dose adjustments may be required depending on the 
conception thyroid test and it is important that local arrangements are in place to 
enable ready access to healthcare services on conception.   
Subclinical hypothyroidism 
Unlike overt hypothyroidism it is less certain whether patients with subclinical 
hypothyroidism should be treated with levothyroxine. Subclinical hypothyroidism 
affects 2-3% of pregnant women although higher rates are reported when stringent 
upper TSH limits are applied (28). Progression rates from subclinical to overt disease 
is 2-5% per year and is amplified in individuals with positive TPOAb or TSH 
concentration >10 mU/L (15). In pregnancy a quarter of women with subclinical 
hypothyroidism have persistent TSH elevation five years after delivery (29). The feto-
maternal risks associated with overt hypothyroidism are also seen with subclinical 
hypothyroidism (4) and have been addressed in numerous largely retrospective 
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studies marked by disparities in diagnostic TSH thresholds, study endpoints, and 
timing of assessments (1, 30, 31). Meta-analysis of these studies suggest a 
significant risk of miscarriage and pre-term loss in women with gestational subclinical 
hypothyroidism (2). Recent data from a Chinese national health programme 
(n=184,611 women) showed that even a TSH >2.5 mU/L in the six months before 
conception was associated with small but significant risks of miscarriages and pre-
term delivery (31). 
However, despite the wealth of observational data only a few interventional trials 
have been published (table 1). A controlled trial by Negro et al showed that 
screening and correction of gestational subclinical hypothyroidism (TSH>2.5 mU/L) 
in women classified as low risk for thyroid disease significantly reduced adverse 
pregnancy events compared to no treatment at all (OR ratio 0.43, 95% CI, 0.26, 
0.70).(32). Another study with a cluster trial design showed significant reduction in 
miscarriage and fetal macrosomia rates from treating subclinical hypothyroidism 
(TSH 2.5-10.0 mU/L) (33). In contrast one observational study reported no difference 
in rates of pregnancy loss between women with subclinical hypothyroidism who 
received levothyroxine and those who did not (34). A 2017 retrospective cohort study 
using an administrative US database comprising 5405 women with subclinical 
hypothyroidism (TSH 2.5-10.0 mU/L) observed that treatment of subclinical 
hypothyroidism led to reductions in pregnancy loss but surprisingly showed an 
increased risk of pre-term delivery, gestational diabetes, and eclampsia (35). 
Two well-conducted randomised controlled trials investigated the benefits of 
maternal screening and levothyroxine treatment on child cognition (36). The 
controlled antenatal thyroid screening study (CATS) randomised 21,846 pregnant 
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women to a screening or control group and treated the screened group with 
levothyroxine if they had subclinical hypothyroidism or hypothyroxinaemia (36). IQ 
scores evaluated at 3 years were not different between offspring of treated and 
untreated women. In the second study 677 women with subclinical hypothyroidism 
and 526 with hypothyroxinaemia were randomly assigned to receive levothyroxine or 
placebo (37). Similarly, no differences in IQ were observed between children of 
treated and untreated mothers tested from 3-5 years of age. Pooled analysis of both 
trials (38) as well as a follow-up evaluation of the CATS child cohort at nine years 
also failed to show differences in IQ scores (39). Several explanations have been 
proposed to reconcile these findings including late treatment initiation (median 
gestational age 13-18 weeks), possible over-treatment (CATS cohort), and high loss 
to follow up (CATS cohort).  
Thus, pending further trials there is insufficient evidence to support a consistent 
therapeutic policy for gestational subclinical hypothyroidism. In agreement with most 
international guidelines we recommend treating women with positive antibodies, TSH 
>10 mU/L, and other risk factors for thyroid dysfunction (table 3). Women with 
infertility or recurrent pregnancy loss should be offered levothyroxine on the basis 
that it could potentially improve fertility and delivery rates (40, 41). Treatment should 
also be considered in women who do not fall into any of the risk categories. It is 
reasonable to discuss the uncertainties with the patient and reach a shared decision 
taking into account the potential but unproven benefits of therapy together with the 
safety of levothyroxine in pregnancy when carefully monitored in a specialist 
antenatal clinic. It should be noted that the definition of subclinical hypothyroidism in 
the preconception stage should be based on the non-pregnant reference range and 
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not the ATA treatment threshold of 2.5 mU/L. More so, borderline results should be 
re-checked 6-8 weeks later before establishing the diagnosis. 
Isolated hypothyroxinaemia 
Isolated hypothyroxinaemia refers to the biochemical finding of a low FT4 in 
conjunction with a normal TSH concentration (42). The aetiology of this condition is 
unclear but contributory factors in pregnancy include iodine deficiency, thyroid 
autoimmunity, assay techniques, and maternal characteristics such as age, body 
mass index, and co-existent diabetes (42, 43). The prevalence ranges from 1-10% in 
iodine sufficient countries to 20-30% in deficient areas and depends on the 
diagnostic FT4 threshold as well as the iodine nutrition status of the population (44).  
There is evidence that maternal hypothyroxinaemia adversely affects child cognitive 
and behavioral development. Pop and colleagues reported an 8–10 point deficit in  
mental and motor function scores in infants of women with persistent 
hypothyroxinaemia at 12 weeks gestation compared to children of euthyroid mothers 
(16). Subsequent studies have shown adverse links between hypothyroxinaemia and 
offspring IQ (45), educational performance (46), attention deficit hyperactivity 
disorders (47), and child behavioural problems (48). In a population based 
prospective study involving 3839 mother child pairs Korevaar et al elegantly 
demonstrated an inverted U shaped association between maternal T4 and child IQ 
with deficits of 1.4 – 3.8 points at extremes of FT4 concentrations (45). The 
association with obstetric outcomes is less consistent with some studies reporting 
adverse pregnancy outcomes (49) while others have shown no association with 
adverse perinatal effects (50).  
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Presently there is no evidence that correcting hypothyroxinaemia with levothyroxine 
has any benefits on child neuro-intellectual function. The two randomized controlled 
trials to have addressed this subject to date showed no benefits of maternal 
levothyroxine on child IQ in women with gestational hypothyroxinaemia (36, 37, 39). 
Thus preconception treatment is not recommended (11) although some guidelines 
would consider treatment in early pregnancy (12). As with other uncertainties shared 
treatment decisions can be reached following an open discussion regarding the lack 
of evidence in this area. 
Euthyroid thyroid autoimmunity 
About 10% of pregnant women have positive thyroid antibodies without thyroid 
dysfunction although prevalence rates vary according to ethnicity and iodine nutrition 
(1). Thyroid autoimmunity is more common in women with infertility and recurrent 
pregnancy loss (51), and about a fifth of untreated antibody positive women develop 
an elevated TSH during the course of pregnancy (5) indicating a degree of thyroid 
hormone deficiency. Observational studies have shown an increased risk of 
miscarriages, pre-term birth, and child neuro-intellectual deficits in pregnant women 
with thyroid antibodies (TPOAb) (52) although this association was not confirmed in 
some studies (53). However, the results of meta-analyses support an overall 
increased risk of pregnancy loss in association with maternal thyroid autoimmunity 
(54-56). A cause-effect relationship is unproven but suggested mechanisms include 
the possibility of innate thyroid hormone deficiency, induction of a diffuse 
autoimmune process that promotes rejection of the fetal allograft, and the 
confounding effects of older age in antibody-positive women (57).  
Whether levothyroxine can prevent foetal loss in antibody positive women is 
unproven. Negro et al showed that miscarriage rates in untreated euthyroid TPOAb-
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positive pregnant women was higher than in antibody-positive women who received 
levothyroxine (13.8% vs.3.5%) (5). In a similarly designed study, Nazarpour et al saw 
a reduction in pre-term delivery rates in treated antibody-positive women (58). Other 
trials did not confirm these benefits (59, 60) and levothyroxine had no impact on 
pregnancy loss in TPOAb positive women with TSH<2.5 mU/L (61). Thus, there is 
currently no strong evidence to support routine levothyroxine therapy for women with 
thyroid autoimmunity. Nonetheless, thyroid function should be monitored through 
pregnancy due to the risk of thyroid dysfunction. Two randomised controlled trials, 
the UK TABLET study, and the T4Lifetrial in Holland, are currently investigating the 
effects of Levothyroxine on life birth rates in women with recurrent pregnancy loss. 
Hyperthyroidism 
Hyperthyroidism is diagnosed in 0.1 – 1.0% of all pregnancies in iodine sufficient 
countries (62). The vast majority of cases are due to Graves’ disease although other 
causes like solitary and multiple autonomously functioning nodules are occasionally 
seen in pregnancy (62). In Graves’ disease, hyperthyroidism results from 
unregulated stimulation of the TSH receptor by TRAbs, the pathological disease 
hallmark (63). Three well-established therapies for hyperthyroidism namely 
antithyroid drugs, radioactive iodine, and thyroidectomy have been available for over 
half a century (64). However, therapeutic options in pregnancy are limited to 
antithyroid drugs since radioactive iodine therapy is contraindicated in pregnancy 
and thyroidectomy is rarely used due the risk of surgical morbidity and fetal exposure 
to anaesthetic gases. In pregnancy the combination of maternal hyperthyroidism, 
circulating maternal TRAbs, and antithyroid drug therapy, present significant threats 
to fetal and maternal well-being (figure 3). 
Maternal  hyperthyroidism 
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Uncontrolled hyperthyroidism exerts well recognised effects that includes 
miscarriages, stillbirths, intrauterine growth retardation, maternal hypertension, and 
heart failure (65, 66). These associations were originally documented in early 
hospital series (67) and have subsequently been confirmed in large population 
datasets (68). Women with severe uncontrolled hyperthyroidism may also develop 
cardiovascular complications including hypertension, arrhythmias, and cardiac failure 
(69). Adverse effects are typically seen in association with overt hyperthyroidism 
(elevated FT4 and suppressed TSH) but not with subclinical hyperthyroidism (normal 
FT4 and suppressed TSH) (70) which in most instances reflects the normal 
physiological adaptations in pregnancy.  
Maternal TRAbs 
 In pregnancy circulating maternal TRAbs cross the placenta and can induce fetal 
thyroid dysfunction through actions on TSH receptors on the fetal thyroid gland (71, 
72). Maternal TRAbs are predominantly stimulatory and cause fetal hyperthyroidism 
and goiter although hypothyroidism occasionally occurs from the presence of TRABs 
with inhibitory properties (72). The prevalence of fetal hyperthyroidism is difficult to 
ascertain but hyperthyroidism occurs in about 1-5% of neonates of mothers with 
Graves’ disease (73). Although neonatal hyperthyroidism is typically transient it can 
result in significant morbidity with occasional fatality if unrecognised (73). An 
important consideration is that pregnant women with previous Graves’ disease who 
were rendered hypothyroid by radioiodine therapy or surgery may continue to 
harbour TRAbs thus placing the fetus at risk of thyroid dysfunction (74). In a five year 
prospective study, persistence of TRAb levels 18 months after therapy was seen in 
75% of radioiodine treated patients compared to 30% of post-surgical patients and 
3% of women rendered euthyroid with antithyroid drugs (74).  
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Antithyroid drugs 
The thionamide compounds namely methimazole (MMI), its pro-drug derivative, 
carbimazole (CMZ), and propylthiouracil (PTU) represent the mainstay of therapy for 
hyperthyroidism in pregnancy (75). These compounds reduce thyroid hormone 
secretion through inhibition of thyroid peroxidase coupling and iodination of tyrosine 
residues on thyroglobulin (75). They also have immunosuppressive properties and in 
large doses PTU blocks peripheral T4 to T3 conversion (75). CMZ is available in the 
UK while MMI is prescribed in the US and continental Europe. Outside of pregnancy 
MMI or CMZ (CMZ/MMI) is first line therapy due to a more favourable 
pharmacokinetic and safety profile. Both drugs cross the placenta to the same extent  
and are secreted in breast milk with negligible effects on the thyroid function of 
breast fed neonates (75). 
About 1-5% of patients treated with antithyroid drugs report minor reactions such as 
rash and fever, which resolve with discontinuation and switching to an alternative 
drug (76). Agranulocytosis is a potentially more serious problem that occurs in 0.1-
0.2% of antithyroid drug users particularly patients on high-dose regimens. It 
develops abruptly and is difficult to predict even with routine blood count monitoring. 
Affected patients should stop thionamides and treatment with broad spectrum 
antibiotics is usually required (76). PTU is associated with a potentially fatal liver 
toxicity that occurs in about 1 per 1000 treated pregnant women per year (77). In one 
US series, 22 episodes of PTU related liver failure comprising nine deaths and five 
liver transplants were observed over a 20 year period (78). The course of PTU 
related hepatotoxicity can be catastrophic in pregnancy and a review of six reported 
cases revealed one fatality and two liver transplants (76). Early recognition of cases 
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offers the best hope of survival although the risk of hepatotoxicity is difficult to predict 
from clinical and biochemical monitoring.   
Another concern regarding thionamide use in pregnancy is the risk of congenital 
anomalies. CMZ/MMI is associated with CMZ or MMI embryopathy, a classic cluster 
of anomalies comprising aplasia cutis, choanal atresia, trachea-oesophageal fistula, 
and dysmorphic facial features (79). This association was originally reported in small 
case series but the use of large disease registries have now revealed a more varied 
phenotype (80). Analysis of a Danish birth registry showed a prevalence of birth 
defects following intrauterine exposure to PTU and CMZ/MMI which was 2-4% 
higher than in unexposed children (81). Furthermore, a less severe pattern of 
anomalies was observed for PTU exposure comprising renal tract and head and 
neck anomalies (81). The increased risk of birth defects in association with PTU as 
well as CMZ/MMI exposure has since been confirmed in two meta-analysis 
published in 2015 (82, 83) as well as in a recently published study from a large 
Korean health database (84). 
The above considerations have therefore shaped current policy on the management 
of gestational hyperthyroidism with the goal being to control hyperthyroidism and at 
the same time limit feto-maternal drug exposure (11). Antithyroid drugs should be 
used at the least effective dose that maintains normal thyroid status and where 
treatment is indicated PTU is recommended in the first trimester of pregnancy 
thereby reducing the risk of CMZ/MMI associated teratogenicity. Patients can then 
switch to CMZ/MMI after the first trimester thus curtailing the risk of PTU related 
hepatotoxicity for the remainder of pregnancy. Further studies are needed to clarify 
the safety and effectiveness of this approach since some studies have shown that 
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switching thionamides during pregnancy does not modify anomaly risk (81-83).  A 
review by Laurberg and Andersen identified a high-risk window from gestation week 
6-10 during which antithyroid drug exposure carried the greatest risk of birth defects 
(85) underpinning the need for an effective preconception strategy. 
Preconception management of hyperthyroidism 
The aim of preconception management is to minimise the risk of maternal 
hyperthyroidism and antithyroid drug exposure in subsequent pregnancy (11, 14, 
86). Women of child bearing age with active hyperthyroidism should be counseled on 
the risk of fetal harm from uncontrolled hyperthyroidism and advised to delay 
pregnancy with effective contraception until a stable euthyroid state is achieved (11, 
14). Specific instructions should be provided for all women to inform their healthcare 
practitioners immediately pregnancy is confirmed (11). Definitive therapy with 
radioiodine or surgery is an option for women who intend future pregnancy (11, 14) 
since pregnancy may induce relapse following antithyroid therapy (87). Definitive 
therapy is most suited to women with a high risk of relapse i.e. positive TRAb levels, 
goiter, ophthalmopathy, and severe biochemical disease (figure 4) (64, 88). It is 
important that pregnancy is avoided for six months after radioiodine treatment due to 
the potential for fetal harm from radioiodine exposure (11, 14). Total thyroidectomy 
may be preferable in individuals with high risk of relapse since thyroidectomy is 
usually although not invariably followed by disappearance of circulatory TRAbs (74).  
Several approaches can be adopted in women who are actively trying to conceive 
while still undergoing treatment with antithyroid drugs (89). One option is to switch 
such women from CMZ/MMI to PTU since PTU is the preferred treatment in the first 
trimester (14). Alternatively, MMI/CMZ may be continued up till conception and then 
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switched as early as possible on conception to PTU. This approach restricts the use 
of PTU to the first trimester of pregnancy thus reducing the risk of PTU related 
hepatotoxicity (14). The third approach is to stop antithyroid drugs on conception in 
women with a low risk of relapse i.e. negative TRAb levels, no goiter no 
ophthalmopathy, and low dose thionamide requirements (14) (figure 4). Such women 
should then be monitored for relapse with 2-4 weekly thyroid tests in the immediate 
post-conception period. Patients on the combination of CMZ/MMI and levothyroxine 
should be switched to a titration regimen since the high doses of antithyroid drugs 
could potentially cause fetal hypothyroidism in pregnancy. 
Patients with infertility 
Thyroid dysfunction is associated with varying degrees of gonadal dysfunction which 
are reversible with treatment but are less commonly observed nowadays due to 
earlier disease detection and treatment. (1). Thyrotoxicosis increases sex hormone 
binding globulin (SHBG) concentrations as well as total testosterone, oestradiol, and 
basal and GnRH stimulated gonadotrophin levels while reverse changes are 
observed in hypothyroidism (1). Males with thyroid dysfunction have shown reduced 
libido, erectile dysfunction and defects in spermatogenesis, while reduced 
conception rates, anovulatory cycles, and disruption in embryo implantation have 
been described in women (1).  
The reported prevalence of subclinical hypothyroidism in fertility clinic studies varies 
widely (0.7% to 43%) reflecting discrepancies in assay sensitivities and diagnostic 
criteria (90). In one study women who had unsuccessful fertilisation had a higher 
mean TSH level compared to those who achieved fertilisation (91). The prevalence 
of thyroid autoimmunity was also increased in women attending fertility clinics 
compared to controls (14 vs 8%) (92). A systematic review of 12 studies showed 
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detrimental effects of thyroid autoimmunity on live birth rates (55). Furthermore, a 
small number of trials in fertility clinic patients with subclinical hypothyroidism (40, 
41) or thyroid autoimmunity (60) showed that levothyroxine therapy improved 
pregnancy delivery rates (56). Lastly, hypothyroidism can be induced by controlled 
ovarian stimulation used in preparation for artificial reproduction technology (ART) 
procedures. The mechanism of hypothyroidism following ovarian stimulation is 
believed to be due to the oestrogen surge which increases TBG concentrations 
thereby exaggerating the fall in free thyroid hormone levels and the compensatory 
rise in TSH (90).  
Patients with infertility should therefore be screened for thyroid dysfunction including 
TPOAb measurements. Infertility clinic patients with overt disease should be treated 
aiming for the first trimester TSH of <2.5 mU/L. Women with subclinical 
hypothyroidism should also be offered treatment taking into account the potential for 
benefit and the possibility that pregnancy could worsen thyroid dysfunction. Similar 
considerations apply to women with thyroid autoimmunity and a small dose of 25-50 
mcg is appropriate in this group of patients (11).  
Universal preconception screening 
Current international guidelines do not recommend routine thyroid screening in 
pregnancy or the preconception period, except in women at risk of thyroid 
dysfunction, the so called case finding strategy (11). The rationale behind this 
approach is that the bulk of thyroid disorders in pregnancy are asymptomatic 
subclinical disease with no proven benefits of therapy and that screening could 
generate anxiety and present a risk of harm from over-treatment (93). The argument 
in favour of universal screening however is that thyroid dysfunction is common in 
pregnancy, adversely affects feto-maternal outcomes, and is easily treated with 
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established cost-effective therapies (93). Furthermore, a third of women with 
gestational thyroid dysfunction are not identified with existing case-finding strategies 
(94) which is less cost-effective than universal screening (95). In reality current 
clinical practice is approaching universal screening driven by increasing public and 
clinician awareness (96). In one hospital study, 85% of pregnant women had thyroid 
tests performed (96) and almost half of European thyroidologists reported that they 
screened all women in pregnancy (97). Further studies are required to understand 
current screening practices as non-systematic screening could ultimately result in 
care inequities with the risk of neglecting disadvantaged populations.  
Conclusions 
Endocrinologists and general clinicians will increasingly encounter women with 
thyroid disorders many of whom will require preconception advice. Optimal 
administrative set-ups for preconception services will vary with local resources but 
because many pregnancies are unplanned clinicians should address future 
pregnancy during routine clinical encounters. Further studies are required to 
determine best policy in women with subclinical hypothyroidism, hypothyroxinaemia, 
and thyroid autoimmunity as well as safe strategies for antithyroid drug use in the 
peri-conception period. The controversies regarding thyroid disease screening are 
unlikely to be resolved without additional adequately powered trials. A preconception 
recruitment design will be central to the success of future studies and although this 
will be challenging to achieve, recruitment hurdles could be overcome through 
collaborative multinational efforts. 
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